Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (4): 362-368.DOI: 10.3969/j.issn.1673-8640.2026.04.008
Previous Articles Next Articles
WANG Yuan1, CHEN Dan2, HUANG Na3(
)
Received:2024-12-08
Revised:2025-06-16
Online:2026-04-30
Published:2026-05-07
CLC Number:
WANG Yuan, CHEN Dan, HUANG Na. Role of red blood cell distribution width-to-platelet count ratio in predicting the short-term prognosis of patients with ARDS based on the datum analysis of MIMIC-Ⅳ database[J]. Laboratory Medicine, 2026, 41(4): 362-368.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.04.008
| 组别 | 例数 | 年龄/岁 | 男性/[例(%)] | 血氧饱和度/% |
|---|---|---|---|---|
| 存活组 | 366 | 58.00 (47.25,67.00) | 219 (59.84) | 81.16 (74.70,88.00) |
| 死亡组 | 225 | 66.00 (55.00,73.00) | 125 (55.56) | 85.13 (78.27,90.32) |
| 统计值 | -4.97 | 1.05 | -3.54 | |
| P值 | <0.001 | 0.306 | <0.001 | |
| 组别 | 动脉氧分压/% | 氧合指数/mmHg | SOFA评分/分 | APS Ⅲ评分/分 |
| 存活组 | 51.00 (40.00,66.75) | 72.99 (55.00,112.96) | 7.00 (4.00,9.00) | 50.00 (39.00,67.75) |
| 死亡组 | 66.00 (48.97,82.00) | 86.28 (68.00,125.00) | 9.00 (6.00,12.00) | 64.00 (47.00,86.00) |
| 统计值 | -5.69 | -3.70 | -6.18 | -5.67 |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 |
| 组别 | OASIS评分/分 | 白细胞计数/(×109L-1) | 中性粒细胞计数/(×109L-1) | 血小板计数/(×109L-1) |
| 存活组 | 37.00 (31.00,42.00) | 10.75 (8.43,13.20) | 9.48 (6.98,12.21) | 252.00 (193.00,321.00) |
| 死亡组 | 38.00 (32.00,45.00) | 19.50 (7.50,25.20) | 15.05 (7.23,21.12) | 155.00 (106.00,205.00) |
| 统计值 | -2.08 | -11.32 | -8.11 | -10.8 |
| P值 | 0.037 | <0.001 | <0.001 | <0.001 |
| 组别 | 血红蛋白/(g·L-1) | 红细胞分布宽度/% | RPR/% | 高血压/[例(%)] |
| 存活组 | 11.40 (9.60,13.20) | 14.10 (13.20,15.30) | 5.62 (4.42,7.35) | 127 (34.70) |
| 死亡组 | 11.20 (8.90,12.50) | 14.60 (13.40,17.20) | 9.44 (7.30,15.87) | 92 (40.89) |
| 统计值 | -2.20 | -4.57 | -11.28 | 2.29 |
| P值 | 0.028 | <0.001 | <0.001 | 0.13 |
| 组别 | 2型糖尿病/[例(%)] | 慢性心力衰竭/[例(%)] | 机械通气/[例(%)] | 使用激素/[例(%)] |
| 存活组 | 103 (28.14) | 44 (12.02) | 351 (95.90) | 239 (65.30) |
| 死亡组 | 83 (36.89) | 46 (20.44) | 211 (93.78) | 144 (64.00) |
| 统计值 | 4.94 | 7.66 | 1.35 | 0.1 |
| P值 | 0.026 | 0.006 | 0.246 | 0.748 |
| 组别 | 例数 | 年龄/岁 | 男性/[例(%)] | 血氧饱和度/% |
|---|---|---|---|---|
| 存活组 | 366 | 58.00 (47.25,67.00) | 219 (59.84) | 81.16 (74.70,88.00) |
| 死亡组 | 225 | 66.00 (55.00,73.00) | 125 (55.56) | 85.13 (78.27,90.32) |
| 统计值 | -4.97 | 1.05 | -3.54 | |
| P值 | <0.001 | 0.306 | <0.001 | |
| 组别 | 动脉氧分压/% | 氧合指数/mmHg | SOFA评分/分 | APS Ⅲ评分/分 |
| 存活组 | 51.00 (40.00,66.75) | 72.99 (55.00,112.96) | 7.00 (4.00,9.00) | 50.00 (39.00,67.75) |
| 死亡组 | 66.00 (48.97,82.00) | 86.28 (68.00,125.00) | 9.00 (6.00,12.00) | 64.00 (47.00,86.00) |
| 统计值 | -5.69 | -3.70 | -6.18 | -5.67 |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 |
| 组别 | OASIS评分/分 | 白细胞计数/(×109L-1) | 中性粒细胞计数/(×109L-1) | 血小板计数/(×109L-1) |
| 存活组 | 37.00 (31.00,42.00) | 10.75 (8.43,13.20) | 9.48 (6.98,12.21) | 252.00 (193.00,321.00) |
| 死亡组 | 38.00 (32.00,45.00) | 19.50 (7.50,25.20) | 15.05 (7.23,21.12) | 155.00 (106.00,205.00) |
| 统计值 | -2.08 | -11.32 | -8.11 | -10.8 |
| P值 | 0.037 | <0.001 | <0.001 | <0.001 |
| 组别 | 血红蛋白/(g·L-1) | 红细胞分布宽度/% | RPR/% | 高血压/[例(%)] |
| 存活组 | 11.40 (9.60,13.20) | 14.10 (13.20,15.30) | 5.62 (4.42,7.35) | 127 (34.70) |
| 死亡组 | 11.20 (8.90,12.50) | 14.60 (13.40,17.20) | 9.44 (7.30,15.87) | 92 (40.89) |
| 统计值 | -2.20 | -4.57 | -11.28 | 2.29 |
| P值 | 0.028 | <0.001 | <0.001 | 0.13 |
| 组别 | 2型糖尿病/[例(%)] | 慢性心力衰竭/[例(%)] | 机械通气/[例(%)] | 使用激素/[例(%)] |
| 存活组 | 103 (28.14) | 44 (12.02) | 351 (95.90) | 239 (65.30) |
| 死亡组 | 83 (36.89) | 46 (20.44) | 211 (93.78) | 144 (64.00) |
| 统计值 | 4.94 | 7.66 | 1.35 | 0.1 |
| P值 | 0.026 | 0.006 | 0.246 | 0.748 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| RPR | 0.776(0.737,0.816) | 6.76% | 71 | 80 | 0.74 |
| SOFA评分 | 0.651(0.605,0.697) | 10.5分 | 86 | 37 | 0.67 |
| APS Ⅲ评分 | 0.639(0.592,0.685) | 60.5分 | 65 | 56 | 0.63 |
| RPR+SOFA评分 | 0.746(0.703,0.788) | 0.45 | 66 | 60 | 0.69 |
| RPR+APS Ⅲ评分 | 0.755(0.715,0.796) | 0.51 | 69 | 58 | 0.58 |
| RPR+APS Ⅲ评分+SOFA评分 | 0.752(0.711,0.793) | 0.54 | 62 | 64 | 0.62 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| RPR | 0.776(0.737,0.816) | 6.76% | 71 | 80 | 0.74 |
| SOFA评分 | 0.651(0.605,0.697) | 10.5分 | 86 | 37 | 0.67 |
| APS Ⅲ评分 | 0.639(0.592,0.685) | 60.5分 | 65 | 56 | 0.63 |
| RPR+SOFA评分 | 0.746(0.703,0.788) | 0.45 | 66 | 60 | 0.69 |
| RPR+APS Ⅲ评分 | 0.755(0.715,0.796) | 0.51 | 69 | 58 | 0.58 |
| RPR+APS Ⅲ评分+SOFA评分 | 0.752(0.711,0.793) | 0.54 | 62 | 64 | 0.62 |
| 项目 | β值 | 标准误 | Wald χ2值 | HR值 (95%CI) | P值 |
|---|---|---|---|---|---|
| 年龄 | 0.02 | 0.00 | 4.91 | 1.02 (1.01 ~ 1.03) | <0.001 |
| 血氧饱和度 | 0.02 | 0.01 | 2.93 | 1.02 (1.01 ~ 1.03) | 0.003 |
| 动脉氧分压 | 0.01 | 0.00 | 5.50 | 1.01 (1.01 ~ 1.02) | <0.001 |
| 氧合指数 | 0.01 | 0.00 | 3.08 | 1.01 (1.01 ~ 1.01) | 0.002 |
| SOFA评分 | 0.13 | 0.02 | 7.35 | 1.13 (1.10 ~ 1.17) | <0.001 |
| APS Ⅲ评分 | 0.02 | 0.00 | 6.43 | 1.02 (1.01 ~ 1.02) | <0.001 |
| RPR | 1.77 | 0.17 | 10.69 | 5.90 (4.26 ~ 8.17) | <0.001 |
| 白细胞计数 | 0.35 | 0.02 | 17.43 | 1.42 (1.36 ~ 1.47) | <0.001 |
| 中性粒细胞计数 | 0.14 | 0.01 | 16.77 | 1.15 (1.13 ~ 1.17) | <0.001 |
| 血小板计数 | -0.01 | 0.00 | -10.20 | 0.99 (0.99 ~ 0.99) | <0.001 |
| 血红蛋白浓度 | -0.06 | 0.03 | -2.32 | 0.94 (0.89 ~ 0.99) | 0.021 |
| 红细胞分布宽度 | 0.14 | 0.02 | 6.50 | 1.15 (1.10 ~ 1.20) | <0.001 |
| 糖尿病 | 0.31 | 0.14 | 2.26 | 1.37 (1.04 ~ 1.79) | 0.024 |
| 慢性心力衰竭 | 0.47 | 0.17 | 2.84 | 1.60 (1.16 ~ 2.21) | 0.005 |
| 项目 | β值 | 标准误 | Wald χ2值 | HR值 (95%CI) | P值 |
|---|---|---|---|---|---|
| 年龄 | 0.02 | 0.00 | 4.91 | 1.02 (1.01 ~ 1.03) | <0.001 |
| 血氧饱和度 | 0.02 | 0.01 | 2.93 | 1.02 (1.01 ~ 1.03) | 0.003 |
| 动脉氧分压 | 0.01 | 0.00 | 5.50 | 1.01 (1.01 ~ 1.02) | <0.001 |
| 氧合指数 | 0.01 | 0.00 | 3.08 | 1.01 (1.01 ~ 1.01) | 0.002 |
| SOFA评分 | 0.13 | 0.02 | 7.35 | 1.13 (1.10 ~ 1.17) | <0.001 |
| APS Ⅲ评分 | 0.02 | 0.00 | 6.43 | 1.02 (1.01 ~ 1.02) | <0.001 |
| RPR | 1.77 | 0.17 | 10.69 | 5.90 (4.26 ~ 8.17) | <0.001 |
| 白细胞计数 | 0.35 | 0.02 | 17.43 | 1.42 (1.36 ~ 1.47) | <0.001 |
| 中性粒细胞计数 | 0.14 | 0.01 | 16.77 | 1.15 (1.13 ~ 1.17) | <0.001 |
| 血小板计数 | -0.01 | 0.00 | -10.20 | 0.99 (0.99 ~ 0.99) | <0.001 |
| 血红蛋白浓度 | -0.06 | 0.03 | -2.32 | 0.94 (0.89 ~ 0.99) | 0.021 |
| 红细胞分布宽度 | 0.14 | 0.02 | 6.50 | 1.15 (1.10 ~ 1.20) | <0.001 |
| 糖尿病 | 0.31 | 0.14 | 2.26 | 1.37 (1.04 ~ 1.79) | 0.024 |
| 慢性心力衰竭 | 0.47 | 0.17 | 2.84 | 1.60 (1.16 ~ 2.21) | 0.005 |
| 项目 | β值 | 标准误 | Wald χ2值 | HR (95%CI) | P值 |
|---|---|---|---|---|---|
| RPR | 1.40 | 0.27 | 5.17 | 4.05 (2.38 ~ 6.88) | <0.001 |
| 动脉氧分压 | 0.01 | 0.00 | 3.83 | 1.01 (1.01 ~ 1.02) | <0.001 |
| 白细胞计数 | 0.29 | 0.02 | 13.23 | 1.34 (1.28 ~ 1.40) | <0.001 |
| 慢性心力衰竭 | 0.49 | 0.18 | 2.75 | 1.63 (1.15 ~ 2.30) | 0.006 |
| 项目 | β值 | 标准误 | Wald χ2值 | HR (95%CI) | P值 |
|---|---|---|---|---|---|
| RPR | 1.40 | 0.27 | 5.17 | 4.05 (2.38 ~ 6.88) | <0.001 |
| 动脉氧分压 | 0.01 | 0.00 | 3.83 | 1.01 (1.01 ~ 1.02) | <0.001 |
| 白细胞计数 | 0.29 | 0.02 | 13.23 | 1.34 (1.28 ~ 1.40) | <0.001 |
| 慢性心力衰竭 | 0.49 | 0.18 | 2.75 | 1.63 (1.15 ~ 2.30) | 0.006 |
| 变量 | 总例数/ [例(%)] | 低RPR组 | 高RPR组 | HR值 (95%CI) | P值 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| 死亡例数/例 | 总例数/例 | 死亡例数/例 | 总例数/例 | ||||||
| 性别 | 0.947 | ||||||||
| 男性 | 344 (58.21) | 26 | 184 | 99 | 160 | 6.00(3.89~9.25) | <0.001 | ||
| 女性 | 247 (41.79) | 20 | 123 | 80 | 124 | 5.70(3.48~9.32) | <0.001 | ||
| 年龄 | 0.115 | ||||||||
| <60岁 | 275 (46.53) | 10 | 153 | 67 | 122 | 11.46(5.89~22.31) | <0.001 | ||
| ≥60岁 | 316 (53.47) | 36 | 154 | 112 | 162 | 4.24(2.90~6.18) | <0.001 | ||
| 高血压 | 0.730 | ||||||||
| 有 | 219 (37.06) | 13 | 92 | 79 | 127 | 6.24(3.47~11.24) | <0.001 | ||
| 无 | 372 (62.94) | 33 | 215 | 100 | 157 | 5.74(3.86~8.53) | <0.001 | ||
| 糖尿病 | 0.648 | ||||||||
| 有 | 186 (31.47) | 10 | 73 | 73 | 113 | 6.59(3.40~12.79) | <0.001 | ||
| 无 | 405 (68.53) | 36 | 234 | 106 | 171 | 5.62(3.85~8.22) | <0.001 | ||
| 慢性心力衰竭 | 0.478 | ||||||||
| 有 | 90 (15.23) | 6 | 38 | 40 | 52 | 7.53(3.17~17.86) | <0.001 | ||
| 无 | 501 (84.77) | 40 | 269 | 139 | 232 | 5.52(3.88~7.86) | <0.001 | ||
| 变量 | 总例数/ [例(%)] | 低RPR组 | 高RPR组 | HR值 (95%CI) | P值 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| 死亡例数/例 | 总例数/例 | 死亡例数/例 | 总例数/例 | ||||||
| 性别 | 0.947 | ||||||||
| 男性 | 344 (58.21) | 26 | 184 | 99 | 160 | 6.00(3.89~9.25) | <0.001 | ||
| 女性 | 247 (41.79) | 20 | 123 | 80 | 124 | 5.70(3.48~9.32) | <0.001 | ||
| 年龄 | 0.115 | ||||||||
| <60岁 | 275 (46.53) | 10 | 153 | 67 | 122 | 11.46(5.89~22.31) | <0.001 | ||
| ≥60岁 | 316 (53.47) | 36 | 154 | 112 | 162 | 4.24(2.90~6.18) | <0.001 | ||
| 高血压 | 0.730 | ||||||||
| 有 | 219 (37.06) | 13 | 92 | 79 | 127 | 6.24(3.47~11.24) | <0.001 | ||
| 无 | 372 (62.94) | 33 | 215 | 100 | 157 | 5.74(3.86~8.53) | <0.001 | ||
| 糖尿病 | 0.648 | ||||||||
| 有 | 186 (31.47) | 10 | 73 | 73 | 113 | 6.59(3.40~12.79) | <0.001 | ||
| 无 | 405 (68.53) | 36 | 234 | 106 | 171 | 5.62(3.85~8.22) | <0.001 | ||
| 慢性心力衰竭 | 0.478 | ||||||||
| 有 | 90 (15.23) | 6 | 38 | 40 | 52 | 7.53(3.17~17.86) | <0.001 | ||
| 无 | 501 (84.77) | 40 | 269 | 139 | 232 | 5.52(3.88~7.86) | <0.001 | ||
| [1] | VIRANI A, MA K, LEAP J, et al. Acute respiratory distress syndrome definition,causes,and pathophysiology[J]. Crit Care Nurs Q, 2019, 42(4):344-348. |
| [2] | REDAELLI S, VON WEDEL D, FOSSET M, et al. Inflammatory subphenotypes in patients at risk of ARDS:evidence from the LIPS-A trial[J]. Intensive Care Med, 2023, 49(12):1499-1507. |
| [3] | DHLAMINI Q, WANG W, FENG G, et al. FGF1 alleviates LPS-induced acute lung injury via suppression of inflammation and oxidative stress[J]. Mol Med, 2022, 28(1):73. |
| [4] | LU W, JI R. Identification of significant alteration genes,pathways and TFs induced by LPS in ARDS via bioinformatical analysis[J]. BMC Infect Dis, 2021, 21(1):852. |
| [5] | WHYTE C S, MORROW G B, MITCHELL J L, et al. Fibrinolytic abnormalities in acute respiratory distress syndrome(ARDS)and versatility of thrombolytic drugs to treat COVID-19[J]. J Thromb Haemost, 2020, 18(7):1548-1555. |
| [6] | LIPPI G, HENRY B M, MATTIUZZI C. Red blood cell distribution width(RDW)reflects disease severity in patients with carbon monoxide poisoning:systematic literature review and meta-analysis[J]. Scand J Clin Lab Invest, 2024, 84(2):79-83. |
| [7] | LIANG L, HUANG L, ZHAO X, et al. Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure[J]. Clin Cardiol, 2022, 45(7):802-813. |
| [8] | ZHAO T, CUI L, LI A. The significance of RDW in patients with hepatocellular carcinoma after radical resection[J]. Cancer Biomark, 2016, 16(4):507-512. |
| [9] | MICHALAK A, GUZ M, KOZICKA J, et al. Red blood cell distribution width derivatives in alcohol-related liver cirrhosis and metabolic-associated fatty liver disease[J]. World J Gastroenterol, 2022, 28(38):5636-5647. |
| [10] | REITSMA S E, PANG J, RAGHUNATHAN V, et al. Role of platelets in regulating activated coagulation factor Ⅺ activity[J]. Am J Physiol Cell Physiol, 2021, 320(3):C365-C374. |
| [11] | MAHMOOD A, SAMAD S, HAIDER H, et al. Association of red blood cell and platelet parameters with metabolic syndrome:a systematic review and meta-analysis of 170 000 patients[J]. Horm Metab Res, 2024, 56(7):517-525. |
| [12] | YILDIRIM F, KARAMAN, KAYA A. Current situation in ARDS in the light of recent studies:classification,epidemiology and pharmacotherapeutics[J]. Tuberk Toraks, 2021, 69(4):535-546. |
| [13] | ZHAO L, SU F, ZHANG N, et al. The impact of the new acute respiratory distress syndrome(ARDS)criteria on Berlin criteria ARDS patients:a multicenter cohort study[J]. BMC Med, 2023, 21(1):456. |
| [14] | HUI Q, ZHANG Q, LI X, et al. Down-regulation of miR-133a-3p protects lung tissue against sepsis-induced acute respiratory distress syndrome by up-regulating SIRT1[J]. Arch Med Sci, 2020, 20(1):289-301. |
| [15] | YAN C, TIAN D, ZHANG C, et al. Evaluation of blood cellular and biochemical parameters in rats under a chronic hypoxic environment at high altitude[J]. Ann Med, 2023, 55(1):898-907. |
| [16] | NAN W, LI S, WAN J, et al. Association of mean RDW values and changes in RDW with in-hospital mortality in ventilator-associated pneumonia(VAP):evidence from MIMIC-IV database[J]. Int J Lab Hematol, 2024, 46(1):99-106. |
| [17] | WU M, ZHOU L, ZHU D, et al. Hematological indices as simple,inexpensive and practical severity markers of obstructive sleep apnea syndrome:a meta-analysis[J]. J Thorac Dis, 2018, 10(12):6509-6521. |
| [18] | JOOSSE H J, VAN OIRSCHOT B A, KOOIJMANS S A A, et al. In-vitro and in-silico evidence for oxidative stress as drivers for RDW[J]. Sci Rep, 2023, 13(1):9223. |
| [19] | ADAMS K, TENFORDE M W, CHODISETTY S, et al. A literature review of severity scores for adults with influenza or community-acquired pneumonia-implications for influenza vaccines and therapeutics[J]. Hum Vaccin Immunother, 2021, 17(12):5460-5474. |
| [20] | XU X, WANG Y, TAO Y, et al. The role of platelets in sepsis:a review[J]. Biomol Biomed, 2024, 24(4):741-752. |
| [21] | CHEN B, YE B, ZHANG J, et al. RDW to platelet ratio:a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B[J]. PLoS One, 2013, 8(7):e68780. |
| [22] | KUMAR A, SAHA D, KINI J, et al. The role of discriminant functions in screening beta thalassemia trait and iron deficiency anemia among laboratory samples[J]. J Lab Physicians, 2017, 9(3):195-201. |
| [23] | JAGODI EJUBOVI A, EJUBOVI M, JAHI R, BRKOVIC A, et al. The role of red cell distribution width(RDW),RDW/platelet ratio,and mean platelet volume as prognostic markers in acute pancreatitis severity and complications based on the bedside index for severity in acute pancreatitis score[J]. Cureus, 2024, 16(8):e66193. |
| [24] | WANG J, CUI L, GUO Z. Predictive value of platelet-related parameters combined with pneumonia severity index score for mortality rate of patients with severe pneumonia[J]. Afr Health Sci, 2023, 23(2):202-207. |
| [25] | GOLWALA Z M, SHAH H, GUPTA N, et al. Mean platelet volume(MPV),platelet distribution width(PDW),platelet count and plateletcrit(PCT)as predictors of in-hospital paediatric mortality:a case-control study[J]. Afr Health Sci, 2016, 16(2):356-362. |
| [26] | KARABULUT B, ARCAGOK B C. New diagnostic possibilities for early onset neonatal sepsis:red cell distribution width to platelet ratio[J]. Fetal Pediatr Pathol, 2020, 39(4):297-306. |
| [27] | GE S, LIN S, ZHANG L, et al. The association of red blood cell distribution width to platelet count ratio and 28-day mortality of patients with sepsis:a retrospective cohort study[J]. Ther Clin Risk Manag, 2020, 16:999-1006. |
| [28] | KIM J H, LEE Y, CHO Y S, et al. A modified simple scoring system using the red blood cell distribution width,delta neutrophil index,and mean platelet volume-to-platelet count to predict 28-day mortality in patients with sepsis[J]. J Intensive Care Med, 2021, 36(8):873-878. |
| [29] | GUPTA A, KUMAR S, ACHARYA S, et al. Utility of platelet indices as prognostic markers of sepsis:a medical intensive care unit-based cross-sectional study at a rural setup[J]. Cureus, 2024, 16(2):e54490. |
| [1] | YANG Li, WANG Jingwen, WANG Xin, ZHANG Yuexin, DUAN Dongkui. Relationship between serum VCAM1,miR-181b-5p and the severity and prognosis of ARDS patients [J]. Laboratory Medicine, 2026, 41(1): 41-46. |
| [2] | GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679. |
| [3] | CHEN Danyang, ZHENG Siyu, ZHENG Ruilin, SU Jingyao, ZHU Bing, LI Yinghua. Research progress in influenza viruses [J]. Laboratory Medicine, 2023, 38(7): 696-703. |
| [4] | GUO Weidong, FU Yun, GAO Shanglan. Relationship between plasma APN,sRAGE and the prognosis of patients with ARDS [J]. Laboratory Medicine, 2021, 36(11): 1097-1100. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||